Profusa, Inc.

NovaBay Pharmaceuticals, trading under the ticker NVAC, filed an 8-K with the SEC on January 22, 2024, relating to its business combination with Profusa, Inc., a California-based medical device and digital health company known for developing implantable biosensor technology for continuous physiological monitoring. Profusa operates in the health technology and medical devices sector, with its core platform focused on tissue-integrating sensors designed to track biomarkers such as oxygen levels over extended periods. The 8-K, filed under accession number 0001213900-24-004961, represents a material corporate event disclosure tied to the transaction. For complete filing history, sponsor details, deal terms, and real-time status updates on NVAC and thousands of other SPAC transactions, sign up for full data access at SpacDesk.